Research graph
References from Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations. Local targets link to admitted publications; unresolved targets remain external evidence.
Bispecific antibodies: from research to clinical application
10.3389/fimmu.2021.626616 · 2021 · External reference
Bispecific antibodies: unleashing a new era in oncology treatment
10.1186/s12943-025-02390-y · 2025 · External reference
Bispecific antibodies in multiple myeloma treatment: a journey in progress
10.3389/fonc.2022.1032775 · 2022 · External reference
Multiple myeloma therapy: emerging trends and challenges
10.3390/cancers14174082 · 2022 · External reference
Bispecific antibody targets and therapies in multiple myeloma
10.3389/fimmu.2024.1424925 · 2024 · External reference
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells
10.1182/bloodadvances.2020002736 · 2021 · External reference
Linvoseltamab for treatment of relapsed/refractory multiple myeloma
10.1200/jco.24.01008 · 2024 · External reference
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
10.1111/bjh.14145 · 2016 · External reference
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
10.1038/s41375-020-0734-z · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis
10.1111/ejh.14348 · 2025 · External reference
Elranatamab in patients with daratumumab relapsed and/or refractory light chain amyloidosis
10.1182/blood-2024-200933 · 2024 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Resistance mechanisms to BCMA targeting bispecific antibodies and CAR T-cell therapies in multiple myeloma
10.3390/cells14141077 · 2025 · External reference
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
10.1182/blood.2023023557 · 2024 · External reference
Epigenetic modifications as a mechanism of resistance to BCMA-directed immunotherapies in multiple myeloma: insights from multi-omic profiling
10.1182/blood-2024-198117 · 2024 · External reference
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms
10.1182/blood.2023022499 · 2024 · External reference
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
10.1038/s41591-023-02491-5 · 2023 · External reference
Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM
10.1182/bloodadvances.2021004418 · 2021 · External reference
Cell-surface tethered promiscuous biotinylators enable comparative small-scale surface proteomic analysis of human extracellular vesicles and cells
10.7554/elife.73982 · 2022 · External reference
DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput
10.1038/s41592-019-0638-x · 2020 · External reference
NF-AT components define a family of transcription factors targeted in T-cell activation
10.1038/369497a0 · 1994 · External reference
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
10.1038/nmeth.4169 · 2017 · External reference
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix
10.1107/s2059798319011471 · 2019 · External reference
MolProbity: more and better reference data for improved all-atom structure validation
10.1002/pro.3330 · 2018 · External reference
Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity
10.1038/s41392-023-01686-z · 2023 · External reference
Highly accurate protein structure prediction with AlphaFold
10.1038/s41586-021-03819-2 · 2021 · External reference
Timing genomic antigen loss in multiple myeloma treated with T cell–redirecting immunotherapies
10.1158/2643-3230.bcd-25-0005 · 2025 · External reference
BCMA extracellular domain functional hotspots and resistance to variable anti-BCMA T cell engagers in multiple myeloma
10.1182/blood-2024-211833 · 2024 · External reference
Differential impact of BCMA (TNFRSF17) extracellular domain mutations on in vitro potency of elranatamab versus teclistamab
10.1016/s2152-2650(25)03506-2 · 2025 · External reference
Unresolved reference
External reference
Characterization of the BCMA epitope bound by BCMA-CD3 T cell engager elranatamab
10.1200/jco.2024.42.16_suppl.7546 · 2024 · External reference
